MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag164

Медицинская библиотека · The oncologist · 2026

Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review.

Wang Lili, Chen Xinyang, Li Yuanyuan, Chang Hua, Meng Xiangkai

СтатьяКлинический случайОбзорПеревод пока не подготовлен

Аннотация

OBJECTIVE

Ovarian clear cell carcinoma (OCCC) frequently exhibits resistance to conventional chemotherapy with limited treatment options. This study reports a heavily pretreated advanced case with liver metastases to investigate the efficacy of gemcitabine combined with PD-1 inhibitor in such refractory patients.

METHODS

We present a case of stage IIIC OCCC that progressed after first-line platinum-based chemotherapy. The patient was treated with gemcitabine in combination with the PD-1 inhibitor toripalimab. Genetic alterations were analyzed using next-generation sequencing, and PD-L1 expression was assessed by immunohistochemistry (combined positive score [CPS]). Treatment response and safety profiles were regularly monitored.

RESULTS

The combination therapy induced a complete remission lasting over 24 months, with a manageable safety profile. Molecular profiling revealed a loss-of-function mutation in ARID1A, which may enhance tumor sensitivity to gemcitabine, while elevated PD-L1 expression (CPS = 30) may serve as a predictive biomarker for immunotherapy response in OCCC. Notably, the deep and durable clinical response observed suggests a potential synergistic effect between gemcitabine and immunotherapy, wherein ARID1A deficiency-induced chemosensitivity may prime the tumor microenvironment for enhanced immune checkpoint inhibition, offering a compelling rationale for this combination strategy in platinum-resistant OCCC.

CONCLUSION

This study proposes a promising therapeutic strategy for advanced OCCC and supports the clinical value of molecular profiling-guided treatment. Both ARID1A status and PD-L1 expression warrant further validation as potential biomarkers in prospective clinical trials.

Для цитирования: Wang Lili, Chen Xinyang, Li Yuanyuan, Chang Hua, Meng Xiangkai. Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag164.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.